Independent report · Private Markets

HUL and OZiva (Zywie Ventures): Wellbeing Nutrition stake sold to USV

· By Abhinav

Photograph of two people published by Inc42 with its March 2021 report on OZiva's $12 million Series B funding round. · Image: Inc42

Photograph of two people published by Inc42 with its March 2021 report on OZiva's $12 million Series B funding round. · Image: Inc42

Independent report content

DEALHindustan Unilever (HUL) agreed to acquire the remaining 49% of Zywie Ventures Pvt Ltd, owner of the plant-based wellness brand OZiva, for ₹824 Cr in cash, making OZiva a wholly owned subsidiary
DATEAnnounced with HUL's Q3 results on 12 Feb 2026 (Venture Intelligence, NutraIngredients, Whalesbook) or 13 Feb 2026 (Entrackr, the exchange-filing day) · completion on 13 Feb or by 31 Mar 2026: sources conflict
IMPLIED VALUEAbout ₹1,682 Cr for 100% of OZiva (Rupeia arithmetic: ₹824 Cr ÷ 0.49) · about 3.2 times the ₹518 Cr implied by the first 51% in December 2022
FIRST STEPDecember 2022: 51% for ₹264.28 Cr in cash, a mix of new money into the company and a buyout of existing holders · balance 49% to be bought after 36 months on pre-agreed valuation criteria
SAME-DAY EXITHUL's 19.8% of Nutritionalab (Wellbeing Nutrition) sold to USV Pvt Ltd for ₹307 Cr; HUL paid ₹70 Cr cash for it in 2022
OZIVA FINANCIALSFY25 revenue ₹258 Cr (+148%), loss ₹4.5 Cr · NutraIngredients instead says about ₹480 Cr for 2025: unreconciled
SELLER AND USE OF CASHSeller of the 49% not named in the sources read · use of the ₹824 Cr by the sellers not stated
SOURCESFive 2026 reports agree on the deal; HUL's own release (hul.co.in) returned an access error and was not read
THE ACCESS POINT OZiva is now wholly owned by HUL and has no separate listing. Exposure to it is only through HUL's own shares, where it is a very small part of the business.

Executive decision summary

THE BOTTOM LINEHUL has taken full ownership of OZiva, a plant-based nutrition brand it first bought into in December 2022. The ₹824 crore cash price for the last 49% implies about ₹1,682 crore for the whole company, roughly 3.2 times the ₹518 crore implied by the first 51%. On the same day HUL agreed to sell its 19.8% stake in Wellbeing Nutrition to USV for ₹307 crore, so it has concentrated its wellness bets on one brand. OZiva reported FY25 revenue of ₹258 crore, up 148%, with a loss of ₹4.5 crore, though one outlet reports about ₹480 crore for 2025 and the two figures are not reconciled. The completion date is also disputed: 13 February 2026 in two sources, by 31 March 2026 in two others. The seller of the 49% and the use of proceeds are not published. The price is about 1.3% of HUL's annual revenue, so it is a small deal for the buyer.
WHICH INVESTORThe deal fits a consumer-sector reader IF you want a dated example of a large FMCG group paying up for a D2C brand it had an option on. Wait IF you need OZiva's FY26 accounts, the seller list or HUL's own filing: none was found in the sources read.
COMFORT FITD2C brand = a company that sells its products directly to consumers, mostly online. Wholly owned subsidiary = HUL now holds all of the shares. Implied valuation = the price for a part divided by the share it buys, giving a value for 100%. Plant-based wellness = vitamins, proteins and supplements made from plant ingredients.
THE RUPEIA NUMBER₹1,682 Cr. The value of 100% of OZiva implied by HUL paying ₹824 Cr for 49% (Rupeia arithmetic).

1 CLAIM REGISTER: EVIDENCE GRADING

ClaimSourceGradeRupeia assessment
HUL to buy the remaining 49% of Zywie Ventures (OZiva) for ₹824 Cr cashEntrackr; Inc42; Venture Intelligence; NutraIngredients; WhalesbookBEstablished across five outlets; HUL release not read
Announcement date: 12 Feb vs 13 Feb 2026Venture Intelligence, NutraIngredients, Whalesbook; EntrackrCConflict of one day; 13 Feb is the exchange-filing day per Inc42
Completion: 13 Feb 2026 vs by 31 Mar 2026Entrackr, Inc42; Whalesbook, NutraIngredientsDConflict; no completion filing found
First 51% for ₹264.28 Cr in December 2022; balance after 36 monthsEntrackr 2022; Outlook Business 2022BEstablished
HUL sells 19.8% of Nutritionalab to USV for ₹307 CrWhalesbook; NutraIngredients; EntrackrBEstablished
OZiva FY25 revenue ₹258 Cr vs about ₹480 Cr for 2025Entrackr, Inc42, Whalesbook; NutraIngredientsDConflict, unreconciled
Seller of the 49%; use of proceedsNoneDNot published

2 THE DEAL AND THE CONSIDERATION

An OZiva Protein & Herbs for Women tub, as pictured by NutraIngredients with its February 2026 report on Hindustan Unilever's full acquisition of OZiva. · Image: NutraIngredients
An OZiva Protein & Herbs for Women tub, as pictured by NutraIngredients with its February 2026 report on Hindustan Unilever's full acquisition of OZiva. · Image: NutraIngredients
ItemDetail
Buyer and targetHindustan Unilever Ltd; Zywie Ventures Pvt Ltd, which owns the OZiva brand
Stake and priceRemaining 49% for ₹824 Cr in cash; about US$90.9m according to NutraIngredients
ResultOZiva becomes a wholly owned subsidiary of HUL
Announcement12 Feb 2026 with HUL's Q3 results; Entrackr dates it 13 Feb, the day of the exchange filing (Inc42)
Paired transactionHUL's 19.8% of Nutritionalab (Wellbeing Nutrition) goes to USV Pvt Ltd for ₹307 Cr
Pricing basisSources do not state whether ₹824 Cr was set pro rata to a 100% valuation; Venture Intelligence says its article gives no valuation, while Entrackr calls it the "latest transaction" valuation
Calculation (Rupeia)Result
Value of 100% implied by the price₹824 Cr ÷ 0.49 = ₹1,681.6 Cr, about ₹1,682 Cr
Total cash paid for full control₹264.28 Cr + ₹824 Cr = ₹1,088.28 Cr
Net cash across the two 2026 transactions₹824 Cr − ₹307 Cr = ₹517 Cr
Price in dollars at ₹96.5 per US$₹8,240 million ÷ 96.5 = US$85.4m
Exchange rate behind NutraIngredients' US$90.9m₹8,240 million ÷ 90.9 = ₹90.6 per US$, an older rate
Deal against HUL's FY26 revenue of ₹63,636 Cr₹824 Cr ÷ ₹63,636 Cr = 1.3%
RUPEIA READ The price is firm across the sources, but the valuation behind it is an inference. It follows only if the 49% was priced on a straight pro-rata basis, which no source states. Against HUL's size the outlay is small, so the deal matters more as a signal about how HUL treats wellness than as a financial event.

3 HOW THE STAKE WAS BUILT: 2022 TO 2026

ItemDetailSource
First step, December 202251% of OZiva for ₹264.28 Cr in cash; a mix of primary infusion and secondary buyoutEntrackr 2022; Outlook Business
Option on the balanceRemaining 49% to be bought at the end of 36 months on pre-agreed valuation criteriaOutlook Business, Dec 2022
Nutritionalab, December 202219.8% for ₹70 Cr cash; HUL's total outlay across both deals about ₹335 CrOutlook Business
Second step, February 202649% for ₹824 Cr; full ownershipFive 2026 sources
Valuation movementEntrackr describes the valuation as up more than threefold over about three yearsEntrackr 2026
Calculation (Rupeia)Result
Value of 100% implied in 2022₹264.28 Cr ÷ 0.51 = ₹518.2 Cr
Value of 100% implied in 2026₹824 Cr ÷ 0.49 = ₹1,681.6 Cr
Change in implied value₹1,681.6 Cr ÷ ₹518.2 Cr = 3.2x
Price per percentage point, 2026₹824 Cr ÷ 49 = ₹16.82 Cr
2022 outlay across both deals₹264.28 Cr + ₹70 Cr = ₹334.28 Cr, matching the ₹335 Cr reported
Time from the December 2022 announcement to February 202636 months + 2 months = 38 months, against the 36-month design
RUPEIA READ The threefold rise in implied value agrees with Entrackr's own description, which supports the arithmetic. HUL paid roughly three times as much per percentage point for the second tranche as for the first, but the 2022 figure included new money into the company, so the two prices are not like for like. The structure worked as a call option: HUL fixed the rules in 2022 and paid the higher price only after the brand had grown.

4 OZIVA FINANCIALS AND THE REVENUE CONFLICT

₹ CrFY21FY22FY24FY25
Revenue from operations72.1124.17 (+72%)104258 (+148%); 257.67 turnover per Whalesbook
Loss9.77Not found43.54.5 (down 90%)
PointDetailSource
FY22 and FY21Revenue ₹124.17 Cr, up from ₹72.1 Cr; FY21 loss ₹9.77 CrEntrackr 2022
FY24 and FY25Revenue ₹104 Cr to ₹258 Cr; loss ₹43.5 Cr to ₹4.5 CrEntrackr 2026; Inc42 matches
Conflicting figureRevenue "approximately Rs 480 crore in 2025", two-year CAGR of 130%NutraIngredients
FY23Not published in the sources read
Calculation (Rupeia)Result
FY22 growth₹124.17 Cr ÷ ₹72.1 Cr = 1.72x, so +72.2%
FY25 growth₹258 Cr ÷ ₹104 Cr = 2.48x, so +148.1%
Reduction in loss₹4.5 Cr ÷ ₹43.5 Cr = 10.3%, so the loss fell 89.7%
FY25 loss margin₹4.5 Cr ÷ ₹258 Cr = 1.7%
FY24 revenue against FY22₹104 Cr ÷ ₹124.17 Cr = 0.84x, so −16.2%; the two years may use different measures
Gap between the two FY25 figures₹480 Cr − ₹258 Cr = ₹222 Cr; ₹480 Cr ÷ ₹258 Cr = 1.9x
Price to sales₹1,681.6 Cr ÷ ₹258 Cr = 6.5x; ₹1,681.6 Cr ÷ ₹480 Cr = 3.5x
RUPEIA READ Three sources give ₹258 crore for FY25, and one gives ₹480 crore; the latter may describe sales at consumer prices or a later run-rate, but it does not say. Whichever is right, the implied price is between 3.5 and 6.5 times revenue, which is a wide band. OZiva is close to break-even, but it was loss-making in the last year reported.

5 THE NUTRITIONALAB EXIT AND THE USV DEAL

ItemDetailSource
HUL's 2022 stake19.8% of Nutritionalab for ₹70 Cr cashOutlook Business
2026 sale19.8% to USV Pvt Ltd for ₹307 CrWhalesbook; NutraIngredients; Entrackr
USV transaction79% of Wellbeing Nutrition at a valuation of about ₹1,583 CrEntrackr
Wellbeing Nutrition scaleFY25 revenue about ₹170 Cr, loss about ₹30 Cr; target above ₹450 Cr revenue by FY27, a company claimEntrackr, Feb 2026
Calculation (Rupeia)Result
Multiple on HUL's ₹70 Cr₹307 Cr ÷ ₹70 Cr = 4.4x
Value of 100% implied by HUL's sale₹307 Cr ÷ 0.198 = ₹1,550.5 Cr
Entrackr's valuation against that figure₹1,583 Cr ÷ ₹1,550.5 Cr = 1.021x, so 2.1% apart and consistent
Target against FY25 revenue₹450 Cr ÷ ₹170 Cr = 2.6x
Price to sales₹1,583 Cr ÷ ₹170 Cr = 9.3x, against 6.5x for OZiva
HUL's net cash across both brands, 2022 to 2026₹334.28 Cr + ₹824 Cr = ₹1,158.28 Cr; then ₹1,158.28 Cr − ₹307 Cr = ₹851.28 Cr
RUPEIA READ HUL made about 4.4 times its money on the minority stake that it chose to sell, and kept and expanded the brand with the smaller loss. The two choices point the same way: HUL has kept the business it controls and left the one it only partly owned. The figures on Wellbeing Nutrition are company claims, so the 9.3 times price to sales is indicative.

6 PEOPLE AND TIMELINE

Person or dateRole or eventSource
Priya NairCEO and MD of HUL; search results indicate appointment from 1 Aug 2025 to 31 Jul 2030, previously President, Beauty & Wellbeing at UnileverNutraIngredients; search only
Sanjiv MehtaHUL CEO and MD at the 2022 dealOutlook Business
Aarti Gill and Mihir GadaniOZiva co-founders; search only: Gill described as co-founder and CEO in 2021, and the pair earlier built Fit CircleOutlook Business; NutraIngredients
Avnish ChhabriaFounder and CEO of Wellbeing NutritionOutlook Business 2022
Calculation (Rupeia)Result
Days from 12 Feb to 31 Mar 202616 + 31 = 47 days, the window in which the later completion date falls
Days from 13 Feb to 31 Mar 202615 + 31 = 46 days
Length of the Nair term (search result)31 Jul 2030 − 1 Aug 2025 = about 5 years
RUPEIA READ The deal is the first big wellness transaction announced under the current HUL chief executive, if the search-result appointment date is right, and the second step of an arrangement made under the previous one. The founders' current role and any payment to them are not published.

7 MARKET CONTEXT: FMCG AND D2C

ItemDetailSource
Other 2026 dealsMarico bought 60% of Cosmix; Emami added Trunativ, Brillare and The Man Company; USV took 79% of Wellbeing NutritionSearch summaries, not opened
Crisil count82 rated FMCG firms against 58 D2C firmsCrisil, via search summary
Growth gapD2C revenue about 40% CAGR against about 8% to 9% for FMCGCrisil, via search summary
HUL scaleFY26 revenue from operations ₹63,636 Cr, up 5.3% (one source) or ₹63,763 Cr from continuing operations (another); Health & Wellbeing growth in double digits per ICICI Direct noteSearch summaries; HUL release not read
Calculation (Rupeia)Result
Growth multiple40 ÷ 8 = 5.0x and 40 ÷ 9 = 4.4x the FMCG rate
Firms rated82 + 58 = 140, of which D2C is 58 ÷ 140 = 41.4%
RUPEIA CALCULATION OZiva's FY25 growth of 148% is far above the 40% Crisil gives for D2C overall, and HUL's own growth was 5.3%. The ₹127 crore gap between HUL's two revenue figures is a difference in definition, not a conflict about the deal.

8 RISKS, SCENARIOS AND CHECKLIST

RiskEvidenceSeverityKill condition
Data conflictOZiva FY25 revenue ₹258 Cr vs about ₹480 CrHIGHFiled accounts give the lower figure
Price paidImplied value 3.2 times the 2022 level; 6.5 times revenue on ₹258 CrMEDIUMGrowth stalls after full control
ProfitabilityFY25 loss ₹4.5 Cr after ₹43.5 Cr in FY24MEDIUMLosses widen again
DisclosureSeller, use of proceeds and HUL release not readMEDIUMFiling shows different terms
ExecutionFounders' ongoing role not publishedMEDIUMKey founders leave
ScenarioWhat happensOutcome
BullOZiva grows near FY25's 148% and turns profitable under HUL distributionThe ₹1,682 Cr valuation is seen as fair
BaseGrowth slows to the 40% D2C average and losses stay smallModest effect on HUL
BearRevenue is nearer ₹258 Cr than ₹480 Cr and growth fadesPrice looks high
Investor classFitWhy
HUL shareholderWATCHSmall deal at 1.3% of revenue; the signal is strategic
Consumer-sector researcherFITDated example of an option exercised on a D2C brand
D2C founder or private-market readerFITShows a threefold rise over about three years

Rupeia does not recommend buying or selling any security and is not a SEBI-registered investment adviser or research analyst. Open items are the seller of the 49%, the use of proceeds, the completion date, OZiva's FY26 accounts and HUL's own release.

9 KEY TERMS USED IN THIS REPORT

The terms below are used in this report. Each is explained in plain words.

TermMeaning
Zywie VenturesThe company that owns the OZiva brand.
Wholly owned subsidiaryA company in which the parent holds all the shares.
Primary and secondaryNew shares sold by the company, and existing shares sold by holders.
Implied valuationThe price for a part of a company, scaled up to 100%.
D2CDirect to consumer: selling to buyers without a retailer in between.
CAGRCompound annual growth rate: the yearly growth that links two figures.

Frequently asked questions

What did HUL agree to buy?

The remaining 49% of Zywie Ventures, which owns OZiva, for ₹824 crore in cash, announced on 12 February 2026 with its Q3 results. OZiva is now wholly owned.

What value does the price imply for OZiva?

About ₹1,682 crore for 100%, from ₹824 crore divided by 0.49. This is Rupeia arithmetic, because the sources do not state a valuation.

What did HUL pay in 2022?

₹264.28 crore for 51% in December 2022, implying about ₹518 crore for the whole company. The 2026 implied value is about 3.2 times that.

What is OZiva's revenue?

Most sources give ₹258 crore for FY25, up 148%, with a ₹4.5 crore loss. NutraIngredients gives about ₹480 crore for 2025; the two are not reconciled.

What happened to Wellbeing Nutrition?

HUL agreed to sell its 19.8% stake in Nutritionalab to USV Pvt Ltd for ₹307 crore. HUL had paid ₹70 crore in 2022.

When did the deal complete?

Entrackr and Inc42 say 13 February 2026; Whalesbook and NutraIngredients say by 31 March 2026. No completion filing was found.

Source log

Entrackr: HUL acquires remaining 49% in OZiva for Rs 824 cr

Inc42: HUL completes acquisition of remaining 49% in OZiva

Venture Intelligence: HUL acquires residual 49% in OZiva

NutraIngredients: HUL to fully acquire OZiva for US$90m

Whalesbook: HUL acquires full OZiva stake, sells Nutritionalab

Entrackr: HUL acquires majority stake in OZiva (December 2022)

Outlook Business: HUL to acquire majority stake in OZiva and 19.8% in Wellbeing Nutrition

Entrackr: USV acquires 79% in Wellbeing Nutrition

DISCLAIMER This document is published strictly for informational, educational and academic record-keeping purposes. The publisher is not a SEBI Registered Investment Adviser (RIA) or Research Analyst (RA). It does not constitute personal investment advice, a financial recommendation, or an offer or solicitation to buy, sell or subscribe to any securities. Investments in the securities market are subject to market risks. Read all related documents carefully before investing.